{"classes":[{"categories":[{"measurements":[{"comment":"SAS software does not compute a confidence interval when the estimate is 100%.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"comment":"Cannot be calculated because participants was censored prior to the timepoint.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"SAS software does not compute a confidence interval when the estimate is 100%","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"comment":"Cannot be calculated because participants were censored prior to the timepoint.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"100","value":"77.5"},{"groupId":"OG001","lowerLimit":"55.9","upperLimit":"96.9","value":"76.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.5","upperLimit":"88.7","value":"84.6"},{"groupId":"OG001","lowerLimit":"72.5","upperLimit":"82.1","value":"77.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"380"},{"groupId":"OG001","value":"367"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"comment":"Cannot be calculated because participants were censored prior to the timepoint.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"More than one race"},{"categories":[{"measurements":[{"comment":"SAS software does not compute a confidence interval when the estimate is 100%.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"100"},{"comment":"SAS software does not compute a confidence interval when the estimate is 100%.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"399"}],"units":"Participants"}],"description":"NIH-required analysis. An event for overall survival is death due to any cause. Survival time is defined as time from randomization to the date of death or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. The protocol endpoint is hazard ratio, which is reported in the statistical analysis results. Five-year rate is reported simply as summary data; it is not the outcome measure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin\n\nCisplatin: 100 mg/m2 IV on days 1 and 22 of IMRT\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG000","title":"IMRT + Cisplatin"},{"description":"Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab\n\nCetuximab: 400 mg/m2 IV 5-7 days before IMRT then 250 mg/m2 IV weekly for 7 weeks\n\nIMRT: 35 fractions over 6 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 70 Gy.","id":"OG001","title":"IMRT + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Eligible participants. Data were stratified by ethnicity.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Analysis was to occur after 180 deaths were reported. Analysis occurred after 133 deaths were reported. Maximum follow-up at time of analysis was 6.5 years. Five-year rates are reported here.","title":"Overall Survival by Race","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}